Patents by Inventor Todd M. Kinsella

Todd M. Kinsella has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9970925
    Abstract: A construct system for expressing a reporter protein, as well as a transgenic animal and a screening method employing the same, are provided. In certain embodiments, the construct system is a three component system in which expression of a reporter protein from a reporter construct is induced by a transcription factor that is produced using two other constructs, each producing a different part of the transcription factor. The parts of the transcription factor are ligated together. Expression of the reporter only occurs in tissues in which both of the parts of the transcription factor are produced.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: May 15, 2018
    Assignee: RIGEL PHARMACEUTICALS, INC.
    Inventor: Todd M. Kinsella
  • Patent number: 9845512
    Abstract: Certain aspects of this disclosure relate to a method that comprises contacting a mammalian cell with a glucocorticoid receptor ligand and a myostatin receptor ligand, thereby activating the glucocorticoid receptor and said myostatin receptor. A screening assay employing the same is also provided.
    Type: Grant
    Filed: January 5, 2011
    Date of Patent: December 19, 2017
    Assignee: RIGEL PHARMACEUTICALS, INC.
    Inventor: Todd M. Kinsella
  • Patent number: 9644224
    Abstract: The invention provides methods and compositions for production of a cyclic polymer in a cell free system. In general, the methods of the invention involve ligating first and second recombinant intein domains to a linear synthetic polymer to form a compound containing the structure: D1-X(n)-D2, where D1 is a first catalytic domain of an intein; D2 is a second catalytic domain of an intein; where the second catalytic domain has at its N-terminus a first reactive site for the intein; and X(n) is a polymer of a number n of monomer X, where the polymer N-terminus has a second reactive site for the intein. D1-X(n)-D2 compounds autocatalytically cyclize the X(n) polymer to produce a cyclic polymer. The invention finds use in a variety of drug discovery, clinical and therapeutic applications.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: May 9, 2017
    Assignee: RIGEL PHARMACEUTICALS, INC.
    Inventor: Todd M. Kinsella
  • Patent number: 9040462
    Abstract: The present invention relates to methods and compositions utilizing inteins to generate libraries of cyclic peptides in vivo. The prevent invention also relates to methods for inhibiting protein-protein interaction.
    Type: Grant
    Filed: May 12, 2008
    Date of Patent: May 26, 2015
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James B. Lorens, Todd R. Pray, Todd M. Kinsella, Mark K. Bennett
  • Publication number: 20140150124
    Abstract: A construct system for expressing a reporter protein, as well as a transgenic animal and a screening method employing the same, are provided. In certain embodiments, the construct system is a three component system in which expression of a reporter protein from a reporter construct is induced by a transcription factor that is produced using two other constructs, each producing a different part of the transcription factor. The parts of the transcription factor are ligated together. Expression of the reporter only occurs in tissues in which both of the parts of the transcription factor are produced.
    Type: Application
    Filed: September 26, 2011
    Publication date: May 29, 2014
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventor: Todd M Kinsella
  • Publication number: 20130269046
    Abstract: A non-human animal model for muscle cell atrophy is provided. In certain embodiments, the animal comprises a cell comprising a nuclear genome comprising a biologically active atrogen gene in operable linkage with a reporter construct comprising: i. a first coding sequence for an optically detectable protein; and ii. a second coding sequence for a secreted reporter enzyme; wherein expression of the atrogen gene is induced upon initiation of muscle cell atrophy, thereby resulting in production of the secreted reporter enzyme and the first optically detectable protein by the cell. Screening assays that employ the non-human animal are also provided.
    Type: Application
    Filed: September 26, 2011
    Publication date: October 10, 2013
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventors: Todd M. Kinsella, Donald G. Payan
  • Publication number: 20110177001
    Abstract: Certain aspects of this disclosure relate to a method that comprises contacting a mammalian cell with a glucocorticoid receptor ligand and a myostatin receptor ligand, thereby activating the glucocorticoid receptor and said myostatin receptor. A screening assay employing the same is also provided.
    Type: Application
    Filed: January 5, 2011
    Publication date: July 21, 2011
    Inventor: Todd M. Kinsella
  • Publication number: 20110087002
    Abstract: The invention provides methods and compositions for production of a cyclic polymer in a cell free system. In general, the methods of the invention involve ligating first and second recombinant intein domains to a linear synthetic polymer to form a compound containing the structure: D1-X(n)-D2, where D1 is a first catalytic domain of an intein; D2 is a second catalytic domain of an intein; where the second catalytic domain has at its N-terminus a first reactive site for the intein; and X(n) is a polymer of a number n of monomer X, where the polymer N-terminus has a second reactive site for the intein. D1-X(n)-D2 compounds autocatalytically cyclize the X(n) polymer to produce a cyclic polymer. The invention finds use in a variety of drug discovery, clinical and therapeutic applications.
    Type: Application
    Filed: December 10, 2010
    Publication date: April 14, 2011
    Inventor: Todd M. Kinsella
  • Patent number: 7872096
    Abstract: The invention provides methods and compositions for production of a cyclic polymer in a cell free system. In general, the methods of the invention involve ligating first and second recombinant intein domains to a linear synthetic polymer to form a compound containing the structure: D1-X(n)-D2, where D1 is a first catalytic domain of an intein; D2 is a second catalytic domain of an intein; where the second catalytic domain has at its N-terminus a first reactive site for the intein; and X(n) is a polymer of a number n of monomer X, where the polymer N-terminus has a second reactive site for the intein. D1-X(n)-D2 compounds autocatalytically cyclize the X(n) polymer to produce a cyclic polymer. The invention finds use in a variety of drug discovery, clinical and therapeutic applications.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: January 18, 2011
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventor: Todd M. Kinsella
  • Patent number: 7863222
    Abstract: As noted above, certain aspects of this disclosure relate to a library of nucleic acid vectors, as well as a method for making the same. In certain embodiments, the library of nucleic acid vectors comprises: a plurality of nucleic acid molecules of the following formula: S1—R—S2 wherein, in each nucleic acid of the plurality: S1 and S2 are each at least 15 nucleotides in length; S1 and S2 are complementary to each other along their entire length; either S1 or S2 is complementary along its entire length to a sequence in eukaryotic mRNA; and R is a six base recognition site for a restriction endonuclease; and wherein S1 and S2 vary in nucleotide sequence between different members of the plurality. A method for amplifying a circular nucleic acid is also provided.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: January 4, 2011
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Donald G. Payan, Mary Shen, Simon Yu, Todd M. Kinsella, Yasumichi Hitoshi
  • Publication number: 20100029505
    Abstract: As noted above, certain aspects of this disclosure relate to a library of nucleic acid vectors, as well as a method for making the same. In certain embodiments, the library of nucleic acid vectors comprises: a plurality of nucleic acid molecules of the following formula: S1—R—S2 wherein, in each nucleic acid of the plurality: S1 and S2 are each at least 15 nucleotides in length; S1 and S2 are complementary to each other along their entire length; either S1 or S2 is complementary along its entire length to a sequence in eukaryotic mRNA; and R is a six base recognition site for a restriction endonuclease; and wherein S1 and S2 vary in nucleotide sequence between different members of the plurality. A method for amplifying a circular nucleic acid is also provided.
    Type: Application
    Filed: August 1, 2008
    Publication date: February 4, 2010
    Inventors: Donald G. Payan, Mary Shen, Simon Yu, Todd M. Kinsella, Yasumichi Hitoshi
  • Patent number: 7604951
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a retinoid X receptor as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: October 20, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Todd M. Kinsella, Esteban Masuda, Mark K. Bennett, Justin E. Warner, David C. Anderson
  • Patent number: 7598050
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a chloride intracellular channel 1 (CLIC1) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: October 6, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Patent number: 7566765
    Abstract: The present invention provides heterocyclic compounds having a nine-membered ring of three repeating C—C—N subunits covalently bound to each other through amide bonds, and variable side groups linked to a central C of each subunit. Also described herein are cells containing the cyclic compounds, methods of screening those cells to identify a cyclic compound of interest, and libraries of cyclic compounds and their encoding nucleic acids. The subject compounds may be employed in a variety of research and medical applications, including methods of treating a patient for hepatitis C infection.
    Type: Grant
    Filed: January 10, 2005
    Date of Patent: July 28, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventor: Todd M. Kinsella
  • Patent number: 7566685
    Abstract: The invention relates to methods and compositions utilizing diphtheria toxin for screening purposes. The invention is particularly useful in screening for modulators of IgE synthesis, secretion and switch rearrangement.
    Type: Grant
    Filed: March 28, 2006
    Date of Patent: July 28, 2009
    Assignee: Rigel Pharmacauticals, Inc.
    Inventor: Todd M. Kinsella
  • Patent number: 7563585
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a thioredoxin-like 32 kDa protein (TXNL) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: July 21, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Publication number: 20080261819
    Abstract: The present invention relates to methods and compositions utilizing inteins to generate libraries of cyclic peptides in vivo. The prevent invention also relates to methods for inhibiting protein-protein interaction.
    Type: Application
    Filed: May 12, 2008
    Publication date: October 23, 2008
    Inventors: James B. Lorens, Todd R. Pray, Todd M. Kinsella, Mark K. Bennett
  • Patent number: 7425418
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a retinoid X receptor as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: September 16, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Todd M. Kinsella, Esteban Masuda, Mark K. Bennett, Justin E. Warner, David C. Anderson
  • Patent number: 7422867
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a CLLD8 protein as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: September 9, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Patent number: 7378251
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a thioredoxin-like 32 kDa protein (TXNL) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: May 27, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson